Raoudha Soufi-Mahjoubi

Raoudha Soufi-Mahjoubi

UNVERIFIED PROFILE

Are you Raoudha Soufi-Mahjoubi?   Register this Author

Register author
Raoudha Soufi-Mahjoubi

Raoudha Soufi-Mahjoubi

Publications by authors named "Raoudha Soufi-Mahjoubi"

Are you Raoudha Soufi-Mahjoubi?   Register this Author

4Publications

80Reads

49Profile Views

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

J Clin Oncol 2013 Nov 30;31(32):4060-6. Epub 2013 Sep 30.

Ignace B. Vergote, University Hospital Leuven, Leuven; Christine Gennigens, Centre Hospitalier Universitaire de Liège, Liège; Luc Y. Dirix, Gasthuis Zusters Antwerpen, Antwerp, Belgium; Agustin Garcia, University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles; John Micha, Gynecologic Oncology Associates, Newport Beach; Emad N. Ibrahim, Beaver Medical Group, Redlands; Abraham C.F. Leung, Carol Zhao, and Raoudha Soufi-Mahjoubi, Nektar Therapeutics, San Francisco, CA; Charles Pippitt, Piedmont Hematology Oncology Associates, Winston Salem, NC; Johanna Bendell, Sarah Cannon Research Institute, Nashville, TN; Daniel Spitz, Palm Beach Cancer Institute, West Palm Beach, FL; Nicholas Reed, Beatson Oncology Centre, Glasgow; Graham Dark, Freeman Hospital, Newcastle upon Tyne; Chris Poole, University Hospital Coventry, Coventry; Gordon Rustin, Mount Vernon Hospital, Northwood, United Kingdom; Paula M. Fracasso and Linda Duska, University of Virginia Health System, Charlottesville, VA; and Vincent A. Armenio, Pharma Resource, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.1278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878105PMC
November 2013